Norges Bank’s Verrica Pharmaceuticals VRCA Stock Holding History

Norges Bank’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,000	Closed	-$592K	–	2168
2018 Q2	$592K	Buy	+3,000	New	+$588K	﹤0.01%	2087

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

Norges Bank's VRCA Position: Q3 2018 in Review

Norges Bank sold out of Verrica Pharmaceuticals (VRCA) in Q3 2018, closing a stake of 3,000 shares — an estimated $592K sold.

Norges Bank first reported a position in VRCA in Q2 2018 and held it in 1 quarter. The position peaked at $592K in Q2 2018. 45 funds tracked by Wall St. Rank hold VRCA as of Q3 2018.

Norges Bank reported no remaining Verrica Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Norges Bank sold 3,000 Verrica Pharmaceuticals shares in Q3 2018, an estimated $592K.
Norges Bank first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Norges Bank's Verrica Pharmaceuticals position peaked at $592K in Q2 2018.
45 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2018.

Based on Norges Bank's 13F filing for Q3 2018, filed 9 Nov 2018.